Insight

Sergio Cifuentes: Key Changes to My Oncology Practice from ASCO2024

Photo taken from Sergio Cifuentes/X

Jun 17, 2024, 04:08

Sergio Cifuentes: Key Changes to My Oncology Practice from ASCO2024

Sergio Cifuentes, Cancer Research Project Manager at CENEIT México, shared a post on X:

“My 10 Key Changes to My Oncology Practice from ASCO2024,

LA GEJ Adenocarcinoma:
I will now treat patients with perioperative FLOT rather than preoperative CROSS.
Stage III Melanoma:
For patients with clinically involved lymph nodes, I will use neoadjuvant immunotherapy.
Unresectable Stage III EGFR-Mutated NSCLC:
I will use indefinite adjuvant osimertinib.
Limited SCLC:
I will be treated with a year of adjuvant Durvalumabafter CT-RT.
ABC:
For patients progressing on ET + iCDK4/6, I will consider adding abemaciclib to ET.
postMONARCH: improvement in mPFS from 3.9 to 5.6 months. ORR were 23% with abemaciclib vs. 8% without (P = .0008)
HR+ EBC with Low/Ultra-Low HER2:
I will consider T-DXd for initial treatment.
DB-06 study: T-DXd had an HR of 0.62 for PFS compared to chemotherapy, with mPFS of 13.2 months vs. 8.1 months. ORR was 56.5% vs. 32.2%.
HR TNBC:
I will add CBP to ATAX-based chemotherapy (AC-T).
–PEARLY: significant increase in 5-year EFS with carbo (82.3% vs. 75.1%), with a hazard ratio of 0.67 (P = .012).
Advanced ALK+ NSCLC:
I will use Lorlatinib as first-line therapy.
CROWN: 5-year PFS of 60% with lorlatinib vs. 8% with crizotinib, with a significantly longer time to intracranial progression.
mCRC MSI-H/dMMR:
I will offer NIVO ± IPI in a 1L setting.
CM 8HW: NIVO + IPI showed a 79% reduction in the risk of disease progression or death compared to chemotherapy (HR 0.21 [95% CI 0.14–0.32]; P < 0.0001).
Hot Flashes in Men on ADT for Prostate Cancer:
I will try oxybutynin (OXY).
Alliance A222001: a higher dose of OXY significantly reduced daily hot flash scores compared to placebo (P = .002).”

Source: Sergio Cifuentes/X

Abemaciclib Adenocarcinoma Adjuvant osimertinib ASCO2024 ASCO24 cancer CENEIT México Durvalumab lorlatinib neoadjuvant immunotherapy OncoDaily Oncology perioperative FLOT Sergio Cifuentes T-Dxd

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage